146 related articles for article (PubMed ID: 7680375)
1. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
Weber J; Yang JC; Topalian SL; Parkinson DR; Schwartzentruber DS; Ettinghausen SE; Gunn H; Mixon A; Kim H; Cole D
J Clin Oncol; 1993 Mar; 11(3):499-506. PubMed ID: 7680375
[TBL] [Abstract][Full Text] [Related]
2. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of intravenous interleukin-6 in patients with advanced cancer.
Weber J; Gunn H; Yang J; Parkinson D; Topalian S; Schwartzentruber D; Ettinghausen S; Levitt D; Rosenberg SA
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):292-302. PubMed ID: 7520334
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of interleukin-6 in children with solid tumours in relapse.
Bouffet E; Philip T; Negrier C; Ffrench M; Frappaz D; Gentilhomme O; Gianella-Borradori A; Brunat-Mentigny M; Blay JY
Eur J Cancer; 1997 Sep; 33(10):1620-6. PubMed ID: 9389924
[TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.
Atkins MB; Vachino G; Tilg HJ; Karp DD; Robert NJ; Kappler K; Mier JW
J Clin Oncol; 1992 Nov; 10(11):1802-9. PubMed ID: 1403061
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
Gordon MS; Nemunaitis J; Hoffman R; Paquette RL; Rosenfeld C; Manfreda S; Isaacs R; Nimer SD
Blood; 1995 Jun; 85(11):3066-76. PubMed ID: 7538815
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy.
Zamkoff KW; Newman NB; Rudolph AR; Young J; Poiesz BJ
J Biol Response Mod; 1989 Oct; 8(5):539-52. PubMed ID: 2795095
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.
D'Hondt V; Humblet Y; Guillaume T; Baatout S; Chatelain C; Berlière M; Longueville J; Feyens AM; de Greve J; Van Oosterom A
Blood; 1995 May; 85(9):2347-53. PubMed ID: 7537110
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
[TBL] [Abstract][Full Text] [Related]
15. Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.
Keever-Taylor CA; Witt PL; Truitt RL; Ramanujam S; Borden EC; Ritch PS
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):231-43. PubMed ID: 8811498
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung.
Ziegler LD; Palazzolo P; Cunningham J; Janus M; Itoh K; Hayakawa K; Hellstrom I; Hellstrom KE; Nicaise C; Dennin R
J Clin Oncol; 1992 Sep; 10(9):1470-8. PubMed ID: 1517790
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]